Business
Cardiol Therapeutics Announces Pricing of Public Offering of Units
Cardiol Therapeutics Announces Pricing of Public Offering of Units Canada NewsW...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"\n \n \n \n Cardiol Therapeutics Announces Pricing of Public Offering of Units\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n \n \n OAKVILLE, ON\n \n \n ,\n \n Nov. 3, 2021\n \n /CNW/ -\n \n Cardiol Therapeutics Inc.\n \n (NASDAQ: CRDL) (TSX: CRDL)\n \n (\"Cardiol\" or the \"Company\")\n \n , a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease (CVD), announced today the pricing of its previously announced public offering (the \"\n \n Offering\n \n \") of 16,350,000 units of the Company (the \"\n \n Units\n \n \") at a price to the public of\n \n US$3.07\n \n per Unit for gross proceeds of\n \n US$50,194,500\n \n , before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. Each Unit will be comprised of one Class A common share of the Company (each, a \"\n \n Unit Share\n \n \") and one-half of one Class A common share purchase warrant of the Company (each, a \"\n \n Warrant\n \n \"). Each Warrant will entitle the holder thereof to purchase one Class A common share of the Company (each, a \"\n \n Warrant Share\n \n \") at a price of\n \n US$3.75\n \n per Warrant Share, subject to adjustment in certain events, for a period of 36 months following the closing date of the Offering.\n \n \n \n \n \n The Company intends to use the net proceeds from the Offering to advance the Company's research and clinical development programs, additional product development, and for general corporate purposes.\n \n \n \n \n Canaccord Genuity and Cantor Fitzgerald (the \"\n \n Underwriters\n \n \") are acting as joint bookrunners in connection with the Offering.\n \n \n \n \n The Offering is expected to close on or about\n \n November 5, 2021\n \n , subject to the satisfaction of customary closing conditions, including the listing of the Unit Shares to be issued under the Offering and the Warrant Shares to be issued upon the exercise of any Warrants issued under the Offering on the TSX and Nasdaq...